-
EP4225314
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4225314
| EP4225314 - COMBINATION OF ANTIBODY-DRUG CONJUGATE AND PARP1 SELECTIVE INHIBITOR [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 20.06.2024 Database last updated on 24.08.2024 | |
| Former | Request for examination was made Status updated on 14.07.2023 | ||
| Former | The international publication has been made Status updated on 16.04.2022 | ||
| Former | unknown Status updated on 29.10.2021 | Most recent event Tooltip | 26.06.2024 | New entry: Despatch of examination report + time limit | Applicant(s) | For all designated states AstraZeneca UK Limited 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge, Cambridgeshire CB2 0AA / GB | For all designated states Daiichi Sankyo Company, Limited 3-5-1, Nihonbashi Honcho Chuo-ku Tokyo 103-8426 / JP | [2023/33] | Inventor(s) | 01 /
METTETAL II, Jerome Thomas Wilmington, DE 19850-5437 / US | 02 /
ASTANEH, Azadeh Cheraghchi Bashi Cambridge Cambridgeshire CB2 0AA / GB | 03 /
LEO, Elisabetta Cambridge Cambridgeshire CB2 0AA / GB | 04 /
WALLEZ, Yann Cambridge Cambridgeshire CB2 0AA / GB | [2023/33] | Representative(s) | Marks & Clerk LLP 15 Fetter Lane London EC4A 1BW / GB | [2023/33] | Application number, filing date | 21791471.2 | 08.10.2021 | [2023/33] | WO2021IB59232 | Priority number, date | US202063089859P | 09.10.2020 Original published format: US 202063089859 P | [2023/33] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2022074617 | Date: | 14.04.2022 | Language: | EN | [2022/15] | Type: | A1 Application with search report | No.: | EP4225314 | Date: | 16.08.2023 | Language: | EN | The application published by WIPO in one of the EPO official languages on 14.04.2022 takes the place of the publication of the European patent application. | [2023/33] | Search report(s) | International search report - published on: | EP | 14.04.2022 | Classification | IPC: | A61K31/496, A61K31/498, A61K31/4985, A61K39/395, A61P35/00, A61P35/02, C07D401/12, C07D471/04 | [2023/33] | CPC: |
A61K31/496 (EP,IL,KR);
A61K47/6803 (KR);
A61K47/6889 (KR,US);
A61K31/4375 (US);
A61K31/4745 (KR);
A61K31/498 (EP,IL);
A61K31/4985 (EP,IL);
A61K39/395 (EP,IL);
A61K45/06 (KR);
A61K47/545 (US);
A61K47/68037 (EP);
A61K47/6849 (KR);
A61K47/6851 (KR);
A61K47/6855 (EP);
A61P35/00 (EP,IL,KR,US);
A61P35/02 (EP,IL);
C07K16/32 (EP,IL,KR,US);
A61K2300/00 (IL);
C07K2317/24 (EP,IL,KR)
(-)
| C-Set: |
A61K31/496, A61K2300/00 (EP);
A61K31/4985, A61K2300/00 (EP);
A61K31/498, A61K2300/00 (EP);
A61K39/395, A61K2300/00 (EP) | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/33] | Extension states | BA | 27.03.2023 | ME | 27.03.2023 | Validation states | KH | 27.03.2023 | MA | 27.03.2023 | MD | 27.03.2023 | TN | 27.03.2023 | Title | German: | KOMBINATION AUS ANTIKÖRPER-WIRKSTOFF-KONJUGAT UND PARP1-SELEKTIVEM INHIBITOR | [2023/33] | English: | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND PARP1 SELECTIVE INHIBITOR | [2023/33] | French: | ASSOCIATION D'UN ANTICORPS CONJUGUÉ ET D'UN INHIBITEUR SÉLECTIF DE LA PARP1 | [2023/33] | Entry into regional phase | 27.03.2023 | National basic fee paid | 27.03.2023 | Designation fee(s) paid | 27.03.2023 | Examination fee paid | Examination procedure | 27.03.2023 | Examination requested [2023/33] | 27.03.2023 | Date on which the examining division has become responsible | 16.11.2023 | Amendment by applicant (claims and/or description) | 25.06.2024 | Despatch of a communication from the examining division (Time limit: M04) | Fees paid | Renewal fee | 13.09.2023 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [Y]US2017274093 (GOLDENBERG DAVID M [US], et al); | [Y]WO2020022363 (DAIICHI SANKYO CO LTD [JP]); | [YDP]WO2021013735 (ASTRAZENECA AB [SE]) | by applicant | WO9007861 | EP0699754 | EP0705903 | US5821337 | WO9954342 | WO0100245 | WO0231140 | WO2004080976 | WO2007133855 | WO2013120066 | WO2014057687 | WO2015098099 | WO2015115091 | WO2015155998 | WO2017002776 | WO2018212136 | WO2019044947 | WO2021013735 |